Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

@article{Bloomgren2012RiskON,
  title={Risk of natalizumab-associated progressive multifocal leukoencephalopathy.},
  author={Gary Bloomgren and Sandra Richman and Christophe Hotermans and M. Madhusudana Subramanyam and Susan E. Goelz and Amy Natarajan and Sophia N.C. Lee and Tatiana Plavina and James V. Scanlon and Alfred Sandrock and Carmen Bozic},
  journal={The New England journal of medicine},
  year={2012},
  volume={366 20},
  pages={
          1870-80
        }
}
BACKGROUND Progressive multifocal leukoencephalopathy (PML) is associated with natalizumab treatment. We quantified the risk of PML in patients with multiple sclerosis, according to the presence or absence of three risk factors: positive status with respect to anti-JC virus antibodies, prior use of immunosuppressants, and increasing duration of natalizumab treatment. METHODS We used data from postmarketing sources, clinical studies, and an independent Swedish registry to estimate the… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 472 CITATIONS

Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy.

  • Multiple sclerosis and related disorders
  • 2016
VIEW 9 EXCERPTS
CITES BACKGROUND, METHODS & RESULTS
HIGHLY INFLUENCED

Carefully estimating the incidence of natalizumab-associated PML

VIEW 23 EXCERPTS
CITES BACKGROUND, METHODS & RESULTS
HIGHLY INFLUENCED

The use of natalizumab for multiple sclerosis

  • Neuropsychiatric disease and treatment
  • 2017
VIEW 4 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Disease-modifying treatments for multiple sclerosis – a review of approved medications

  • European journal of neurology
  • 2016
VIEW 13 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Body weight-based natalizumab treatment in adult patients with multiple sclerosis

  • Journal of Neurology
  • 2015
VIEW 7 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2010
2019

CITATION STATISTICS

  • 42 Highly Influenced Citations

  • Averaged 58 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 21 REFERENCES

Factors associated with anti-JCV antibody prevalence in a large cohort of naThe New England Journal of Medicine Downloaded from nejm.org at UNIVERSITY OF SOUTH

M Subramanyam, T Plavina, K Simon
  • AUSTRALIA on May
  • 2012

Prevalence of anti-JCV antibodies in a multi-national cohort of multiple sclerosis patients

T Olsson, A Achiron, L Alfredsson
  • Mult Scler J 2011;17:Suppl:S134S135. Copyright © 2012 Massachusetts Medical Society. The New England Journal of Medicine Downloaded from nejm.org at UNIVERSITY OF SOUTH AUSTRALIA on May
  • 2012

JCV epidemiology in MS: epidemiology of anti-JC virus antibody prevalence in multiple sclerosis patients

C Bozic, M Subramanyam, D Paes
  • Mult Scler J
  • 2011

The incidence of PML in natalizumab long-term safety programs is comparable to postmarketing incidence

H Butzkueven, C Polman, S Belachew
  • Mult Scler J 2011;17:Suppl:S519
  • 2011

Anti-JCV antibody prevalence in a Swedish cohort of MS patients and non-MS controls

T Olsson, J Hillert, L Alfredsson
  • Mult Scler J 2010;16:Suppl:S348
  • 2010

Assessment of the incidence of anti-JCV antibodies in a cohort of natalizumabtreated patients with multiple sclerosis

L Gorelik, S Bixler, M Lerner
  • Mult Scler J 2010;16:Suppl:S306-S307
  • 2010

Similar Papers

Loading similar papers…